Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 2,077-2,088 of 4,306
Drug study icon
CompletedNCT00246272

An Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

This study is completed. It focuses on schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.Over 18 Years
Countries
Sponsor
Janssen-Ortho Inc., Canada
Condition
Schizophrenia
Drug study icon
CompletedNCT02320032

An Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

This study is completed in the United States. It is testing aripiprazole Lauroxil for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Alkermes, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT01696929

An study of Tocilizumab in Schizophrenia

This study is completed in the United States. It is testing Open-Label Trial of Tocilizumab for schizophrenia.

In Augusta
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States
Sponsor
Brian Miller
Condition
Schizophrenia
Drug study icon
CompletedNCT01129882

An Rollover, Long-term Study of Aripiprazole Intramuscular Depot in people with Schizophrenia

This study is completed in the United States, in Australia, in Argentina, .... It is testing aripiprazole Intramuscular Depot for schizophrenia.

Multiple locations, including Bellevue
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Australia, Argentina, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
TerminatedNCT01939548

Efficacy, Safety, And Tolerability Of PF-02545920 for schizophrenia

This study was terminated in the United States. It is testing Efficacy, Safety, And Tolerability Of PF-02545920 for schizophrenia.

Multiple locations, including Birmingham
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Pfizer
Condition
Schizophrenia
Drug study icon
CompletedNCT00047450

Antidepressant Treatment in Older Adults With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including San Diego
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugOver 40 Years
Countries
United States
Sponsor
Veterans Medical Research Foundation
Condition
Schizophrenia
Drug study icon
CompletedNCT00493233

Antipsychotic Polypharmacy in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Toronto
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 80 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
Drug study icon
CompletedNCT00018668

Antipsychotic Response in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In San Diego
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 21 Years to 70 Years
Countries
United States
Sponsor
US Department of Veterans Affairs
Condition
Schizophrenia
Drug study icon
CompletedNCT00334035

Antipsychotic Therapy and First Episode

This summary needs review. Please check the official study record and contact the research team for details.

In Hong Kong
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
China
Sponsor
The University of Hong Kong
Condition
Schizophrenia
Device study icon
WithdrawnNCT01979796

Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.

This summary needs review. Please check the official study record and contact the research team for details.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 65 Years
Countries
Sponsor
University of Catania
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.